Invivyd, Inc. (NASDAQ:IVVD) Director Sells $50,318.10 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 119,805 shares of Invivyd stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at $1,498,675.08. This represents a 3.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The stock was sold at an average price of $0.54, for a total value of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total value of $34,099.20.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Trading Down 3.8 %

Shares of Invivyd stock opened at $0.51 on Friday. The business’s fifty day moving average price is $0.73 and its 200 day moving average price is $0.97. Invivyd, Inc. has a twelve month low of $0.40 and a twelve month high of $5.20. The stock has a market capitalization of $61.00 million, a P/E ratio of -0.26 and a beta of 0.53.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently modified their holdings of the company. Duquesne Family Office LLC acquired a new stake in Invivyd during the 2nd quarter worth approximately $629,000. Acadian Asset Management LLC grew its stake in Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after buying an additional 474,301 shares during the period. Cornercap Investment Counsel Inc. acquired a new stake in shares of Invivyd in the second quarter worth $86,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after purchasing an additional 25,201 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IVVD shares. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Invivyd in a report on Thursday, November 21st. Morgan Stanley decreased their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, HC Wainwright cut their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.